One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage. The production of Bacillus ...

Amid a global drug shortage, thousands of patients with bladder cancer are unable to receive their recommended treatment each year. While Merck has pledged to make as many doses as it can, the company ...